{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T06:48:58Z","timestamp":1693637338595},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:p>Familial adenomatous polyposis coli (FAP) is an autosomal dominant condition caused by a germline mutation in the adenomatous polyposis coli gene. Colonic adenomas form and almost all patients will develop colorectal cancer if they are not managed at an early stage. The safest preventive strategy is surgical resection of the colon, most commonly performed in late teenage years. There is a paucity of trials investigating the use of primary chemoprevention to delay polyp formation in paediatric FAP. There are extensive preclinical and early clinical data demonstrating that curcumin may be a safe and effective chemotherapeutic agent in reducing the polyp burden in this disease. We ultimately proposed to design and conduct a clinical study to assess whether curcumin treatment delays the need for surgery and\/or prevents cancer in young patients with FAP. Research into clinical trial protocols has demonstrated that assessing patients\u2019 perceptions at the initial stage leads to better outcomes. We therefore conducted a questionnaire study of patients and parents of children affected by FAP to gain information to aid the protocol design. Results demonstrated that there are some FAP patients for whom this study is relevant and desirable. Those with a personal history of curcumin use reported that it was well tolerated. However, the response rate was poor (25%), indicating that there are potential difficulties ensuring adequate recruitment to the proposed trial. This report draws on lessons learnt from prior trials and the findings from the questionnaire to outline the challenges faced in designing such a study.<\/jats:p>","DOI":"10.1097\/cej.0000000000000256","type":"journal-article","created":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T13:07:03Z","timestamp":1461935223000},"page":"277-284","source":"Crossref","is-referenced-by-count":0,"title":["Assessing barriers to a rational chemoprevention trial design in young patients with familial adenomatous polyposis"],"prefix":"10.1097","volume":"26","author":[{"given":"Joanna P.","family":"Wood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne M.","family":"Howells","sequence":"additional","affiliation":[{"name":"Department of Cancer Studies, University of Leicester"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Cancer Studies, University of Leicester"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne L.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230901","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/sj.ejhg.5201088","article-title":"Frequency and parental origin of de novo APC mutations in familial adenomatous polyposis","volume":"12","author":"Aretz","year":"2004","journal-title":"Eur J Hum Genet"},{"key":"R2-20230901","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/bjs.5276","article-title":"Meta-analysis of observational studies of ileorectal versus ileal pouch-anal anastomosis for familial adenomatous polyposis","volume":"93","author":"Aziz","year":"2006","journal-title":"Br J Surg"},{"key":"R3-20230901","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/BF02054051","article-title":"Changing causes of mortality in patients with familial adenomatous polyposis","volume":"39","author":"Belchetz","year":"1996","journal-title":"Dis Colon Rectum"},{"key":"R4-20230901","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/humu.1380030206","article-title":"Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate","volume":"3","author":"Bisgaard","year":"1994","journal-title":"Hum Mutat"},{"key":"R5-20230901","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1158\/1940-6207.CAPR-11-0106","article-title":"A randomized placebo-controlled prevention trial of aspirin and\/or resistant starch in young people with familial adenomatous polyposis","volume":"4","author":"Burn","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"key":"R6-20230901","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0016-5107(03)02336-8","article-title":"Familial adenomatous polyposis","volume":"58","author":"Cruz-Correa","year":"2003","journal-title":"Gastrointest Endosc"},{"key":"R7-20230901","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.cgh.2006.03.020","article-title":"Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis","volume":"4","author":"Cruz-Correa","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R8-20230901","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0140-6736(03)12342-2","article-title":"Overview of the main outcomes in breast-cancer prevention trials","volume":"361","author":"Cuzick","year":"2003","journal-title":"Lancet"},{"key":"R9-20230901","first-page":"596","article-title":"Patient adherence to pharmacotherapy: the importance of effective communication","volume":"30","author":"DiMatteo","year":"1995","journal-title":"Formulary"},{"key":"R11-20230901","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1600-0528.1999.tb01989.x","article-title":"Prevention and reversal of dental caries: role of low level fluoride","volume":"27","author":"Featherstone","year":"1999","journal-title":"Community Dent Oral Epidemiol"},{"key":"R12-20230901","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1056\/NEJMoa012015","article-title":"Primary chemoprevention of familial adenomatous polyposis with sulindac","volume":"346","author":"Giardiello","year":"2002","journal-title":"N Engl J Med"},{"key":"R13-20230901","first-page":"4756","article-title":"A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients","volume":"9","author":"Higuchi","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R14-20230901","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/CEJ.0000000000000061","article-title":"Cancer chemoprevention: factors influencing attitudes towards chemopreventive agents in high-risk populations","volume":"23","author":"Iwuji","year":"2014","journal-title":"Eur J Cancer Prev"},{"key":"R15-20230901","first-page":"597","article-title":"Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion\/progression stages of colon cancer","volume":"59","author":"Kawamori","year":"1999","journal-title":"Cancer Res"},{"key":"R16-20230901","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1442-2018.1999.00025.x","article-title":"Compliance of adolescents with asthma","volume":"1","author":"Kyng\u00e4s","year":"1999","journal-title":"Nurs Health Sci"},{"key":"R17-20230901","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0016-5085(91)90519-Q","article-title":"Sulindac causes regression of rectal polyps in familial adenomatous polyposis","volume":"101","author":"Labayle","year":"1991","journal-title":"Gastroenterology"},{"key":"R18-20230901","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/ajg.2009.758","article-title":"The safety and efficacy of celecoxib in children with familial adenomatous polyposis","volume":"105","author":"Lynch","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R19-20230901","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.gie.2012.11.038","article-title":"Global quantitative assessment of the colorectal polyp burden in familial adenomatous polyposis by using a web-based tool","volume":"77","author":"Lynch","year":"2013","journal-title":"Gastrointest Endosc"},{"key":"R20-20230901","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/carcin\/21.5.921","article-title":"Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis","volume":"21","author":"Mahmoud","year":"2000","journal-title":"Carcinogenesis"},{"key":"R21-20230901","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1002\/bjs.1800801244","article-title":"Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis","volume":"80","author":"Nugent","year":"1993","journal-title":"Br J Surg"},{"key":"R23-20230901","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/gut.50.6.857","article-title":"A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis","volume":"50","author":"Phillips","year":"2002","journal-title":"Gut"},{"key":"R24-20230901","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJM200006293422603","article-title":"The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis","volume":"342","author":"Steinbach","year":"2000","journal-title":"N Engl J Med"},{"key":"R25-20230901","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/MPG.0b013e318276977d","article-title":"Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study","volume":"56","author":"Suskind","year":"2013","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R26-20230901","first-page":"201","article-title":"Surgical treatment in familial adenomatous polyposis","volume":"25","author":"Tudyka","year":"2012","journal-title":"Ann Gastroenterol"},{"key":"R28-20230901","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/gut.40.6.716","article-title":"Decision analysis in the management of duodenal adenomatosis in familial adenomatous polyposis","volume":"40","author":"Vasen","year":"1997","journal-title":"Gut"},{"key":"R29-20230901","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/gut.2007.136127","article-title":"Guidelines for the clinical management of familial adenomatous polyposis (FAP)","volume":"57","author":"Vasen","year":"2008","journal-title":"Gut"},{"key":"R30-20230901","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1136\/gut.2009.200642","article-title":"Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis","volume":"59","author":"West","year":"2010","journal-title":"Gut"}],"container-title":["European Journal of Cancer Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00008469-201707000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T00:02:44Z","timestamp":1693612964000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008469-201707000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/cej.0000000000000256","relation":{},"ISSN":["0959-8278"],"issn-type":[{"value":"0959-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}